Evidence map›Paper›PMID 29057053›Full record

ArticleACS medicinal chemistry letters2017

Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.

Jiney Jose, Clint D J Tavares, Nancy D Ebelt, Alessia Lodi, Ramakrishna Edupuganti, Xuemei Xie, Ashwini K Devkota, Tamer S Kaoud, Carla L Van Den Berg, Eric V Anslyn and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Impact of the PdInternational journal of molecular sciences · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jiney JoseDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Clint D J TavaresDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Nancy D EbeltDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Alessia LodiDepartment of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas at Austin, Austin, Texas 78723, United States.
Ramakrishna EdupugantiDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Xuemei XieSection of Translational Breast Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Ashwini K DevkotaDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Tamer S KaoudDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Carla L Van Den BergGraduate Program in Cell and Molecular Biology, University of Texas at Austin, Austin, Texas 78712, United States.
Eric V AnslynDepartment of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
Stefano TizianiDepartment of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas at Austin, Austin, Texas 78723, United States.
Chandra BartholomeuszSection of Translational Breast Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Kevin N DalbyDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
The University of Texas at Austin · USThe University of Texas MD Anderson Cancer Center · US

Funding

Novel Therapeutics for Translation Control in Breast CancerR21CA167505 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI DALBY, KEVIN N, OZPOLAT, BULENT · 2012 to 2013
$369k
NCI NIH HHS R21 CA167505
6 · The paper itself

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) is a critical local regulator of epithelial homeostasis in the breast and exerts its actions through a number of receptors. Dysregulation of serotonin signaling is reported to contribute to breast cancer pathophysiology by enhancing cell proliferation and promoting resistance to apoptosis. Preliminary analyses indicated that the potent 5-HT1B/1D serotonin receptor agonist 5-nonyloxytryptamine (5-NT), a triptan-like molecule, induced cell death in breast cancer cell lines. Thus, we synthesized a series of novel alkyloxytryptamine analogues, several of which decreased the viability of various human cancer cell lines. Proteomic and metabolomic analyses showed that compounds

Indexed as

Breast cancerserotonin receptortryptamine

Identifiers

PMID29057053
PMCPMC5641961
OpenAlexW2755703842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.